Buloxibutid ( AT2 receptor agonist C21) (Standard) is the analytical standard of Buloxibutid ( HY-100113 ). This product is intended for research and analytical applications. Buloxibutid is an orally active, selective angiotensin II type 2 receptor ( AT2R ) agonist, with a K i value of 0.4 nM for porcine AT2R . Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13 ) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Others | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > MMP | Products > Signaling Pathways > Angiotensin Receptor | Products > Signaling Pathways > Reference Standards
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye